Basso Tracy 4

What Happened

Tracy Basso, EVP & CHRO of Keenova Therapeutics plc, had restricted stock units (RSUs) vest and be settled into ordinary shares on April 23, 2026. The Form 4 reports conversion/acquisition of 1,523 shares (derivative conversion, code M) and a simultaneous reported disposition of 1,523 shares at $0. No cash proceeds or sale price are reported in the filing. This appears to be a routine compensation vesting event rather than an open-market purchase or sale.

Key Details

• Transaction date: April 23, 2026; Form 4 filed April 24, 2026 (filed within one business day).
• Acquired: 1,523 shares via exercise/conversion of derivative (RSU conversion; code M).
• Disposed: 1,523 shares reported at $0 (no cash proceeds reported).
• Shares owned after transaction: not specified in the provided filing details.
• Footnotes:
  • F1: Each vested RSU was settled in one ordinary share.
  • F2: These RSUs were granted Sept 30, 2024 and vest ratably on Apr 23, 2025, Apr 23, 2026 and Apr 23, 2027.
• Remarks: Filing also serves as notice to the issuer under Part V of the Companies Act 2014.

Context

• This was a derivative/award settlement (RSU vesting), not a market buy or sell. The filing shows no cash sale price; such $0 dispositions in RSU settlements commonly reflect net settlement or withholding to cover taxes, although the Form 4 does not state the reason.
• For retail investors: compensation-related conversions are routine and do not necessarily signal insider sentiment about the stock. Purchases by insiders tend to be more indicative of bullish views.